Fra:
Men bra de gjør grep. Tipper det meste ordner seg nå som navnet blir kortere og mer konkret
3 Likes
Er noen som gnir seg i hendene i det miste, har tydeligvis disse på retainer
Jeg fant motet til meg og gikk inn igjen på fredag. Kursen har gjort alt annet enn å stige i forkant av CMD, spørsmålet er selvfølgelig hvor mye skit skal det nye navnet og logoen kompensere for 
3 Likes
Fjerne «nordisk» og snu oksen, kurs opp 10% imorgen
1 Like
Nå er det derimot snart mulig å gjøre en trade på bunnen her, ikke sikkert voyeuristen vår er helt på jordet:
1 Like
Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture
2026-09-14 09:05:18
Bagsværd, Denmark, 14 September 2026 – Novo Nordisk marked the beginning of its next chapter today by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single ‘Novo’ name, and by updating its culture with ‘ The Novo Way ’ that will enable the company to move ahead with greater focus, speed and impact. Together, the rebrand and ‘ The Novo Way ’ are part of how the company will deliver on its business objectives and its ambition to bring better health to many more people.
“People have always been at the centre of Novo’s science. We have transformed major areas of healthcare, such as obesity and diabetes, by bringing innovation to conditions that affect millions of lives. But the unmet need remains vast, and at the same time, people’s expectations of healthcare are changing,” said Mike Doustdar, president and CEO, Novo. “Healthcare must become more responsive, relevant and easier to fit into everyday life. Our brand and culture are strategically important and will enhance how we operate and compete, but the reason we exist will not change. We remain true to our purpose of changing people’s lives and are ambitious about our future to help them have lasting health, starting right now."
The rebrand
‘ Lasting Health Starts Now’ is at the centre of the rebrand and is based on the idea that lasting health begins today, not someday, through progress people can see and feel day by day. The rebrand will give the company a distinctive, recognisable and consistent way to connect with people, partners and other stakeholders around the world. ‘Novo’ will be used as the name of the company day-to-day, while Novo Nordisk A/S remains the legal global company name. The updated visual identity includes the Apis bull logo rooted in Novo’s heritage, while giving the brand a contemporary and future-fit expression.The rebrand is designed to be more memorable and relevant to the way people engage with their health today. It also reflects the company’s ambition to bring breakthrough science closer to people’s daily lives and to strengthen recognition and trust as Novo reaches more people in more ways.
Corporate culture
‘The Novo Way’, introduced today, is a new set of principles that will underpin the company’s culture, building on the strengths that have defined Novo for more than a century - breakthrough science, deep expertise, care for people, and an unwavering commitment to patient safety - while setting out the behaviours and ways of working needed to innovate and lead in a faster, more competitive and increasingly consumer-driven market.‘ The Novo Way ’ is built around four principles:
- Customer Obsession – We innovate with consumers and patients at the centre of everything we do
- Competitiveness – We raise our performance to create greater value for all our stakeholders
- Clarity – We create focus and speed through clear priorities, simple ways of working and decisive action
- Care & Integrity – We care for our people, show respect, and never compromise on patient safety and ethics
“Brand and culture work together: culture shapes how we reach our strategy and how we work, while brand shapes the value that people attach to our products and services, and how our company is perceived around the world,” said Tania Sabroe, executive vice president, People, Organisation & Corporate Affairs, Novo . “Our updated culture will enable us to move with focus and speed, and our rebrand ensures we show up with relevance and distinctiveness across medicines, partnerships, marketing and stakeholder engagement. Together, these will sharpen our competitive edge and strengthen our role as a trusted partner in healthcare.”
At its Capital Markets Day on 21 September in London, Novo will provide a detailed overview of the updated corporate strategy. Details can be found on the Investor Relations page of novonordisk.com.
To see more of the new Novo brand elements and the Novo Way, go to novonordisk.com
1 Like
Taket på huset lekker.
Novo:
-
Vi graver en vollgrav rundt huset
-
Vi maler veggene
-
Vi lager oss en ny logo til huset vårt
-
Vi snakker om at huset vårt er det aller beste huset
Den dagen selskapet klarer å adressere problemet, elefanten i rommet, så kan det hende at investorene gir det fornyet tillit. Enn så lenge er dette som å se et norsk lag som ligger på nedrykksplass på tabellen i Eliteserien snakke om medaljesjansene sine inneværende sesong.
1 Like
Buy the rumor sell the news? Kursen kan begvege på seg denne uka av potensiell Denecimig CHMP avgjørelse og så EASD annonsering
Ja, my take også.
Se om hypen slår til og selge ut 50 - 60 % før CMD og la resten stå in case de faktisk evner å vekke noe tro på deres fremtid.
Ikke mitt problem om markedet lar seg forlokke av fancy vollgrav og ny kledning.
1 Like
Vi får se, jeg tror det eneste håpet for at markedet får troa på Novo igjen er at de viser noe vettig skyds fra toppen av Bagsværd Slot.
Ingen tror voldsomt på Novos pipe, utenom selskapet selv da.
Jeg vil se noen skudd fra toppen av muren som ikke lander i vollgraven, for å si det sånn
Her skal man liksom være pure play fedme og diabetes, og klarer ikke å dekke alle basene innafor de to feltene engang. Blir bare alt alt alt for teit.
Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026
2026-09-16 09:00:00
- New data will highlight the breadth of semaglutide evidence across the cardiometabolic spectrum, including obesity, type 2 diabetes, cardiovascular, kidney and fatty liver disease, and new data on Wegovy® pill, Wegovy® 7.2 mg and Ozempic® 2.0 mg
- Real-world evidence from the OCTANE study will provide insights into Wegovy® pill use in adults with overweight or obesity, including weight outcomes, treatment switching and patient-reported outcomes
- CagriSema and amylin-based pipeline data will provide new insights into appetite regulation, eating behaviour, food noise, body composition and bone health (bone remodelling mechanisms). The data will advance our understanding of the underlying biology of obesity and type 2 diabetes and inform next-generation cardiometabolic innovation.
Bagsværd, Denmark, 16 September 2026 – Novo Nordisk today announced that new data from its cardiometabolic pipeline and portfolio will be presented at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2026 in Milan, Italy, from 28 September to 2 October. The data to be presented at EASD will bring new scientific insights shared across obesity, type 2 diabetes, cardiovascular, kidney and liver-related outcomes. Together, the presentations reflect Novo’s continued focus on advancing understanding and treatment of interconnected cardiometabolic diseases to help many more patients.
A total of 44 abstracts will be presented, including data across semaglutide, CagriSema, and zenagamtide. Key presentations will include real-world evidence on Wegovy® pill and CagriSema data exploring appetite regulation, eating behaviour and brain responses to food cues using fMRI (functional Magnetic Resonance Imaging; a non-invasive brain scan that shows which areas of the brain are active during specific tasks or while at rest), and CagriSema data in type 2 diabetes looking at body composition, organ-level fat and bone remodelling mechanisms. Additional presentations include data on semaglutide addressing excess liver fat in people with obesity, and real-world evidence comparing major adverse cardiovascular events in adults with type 2 diabetes escalating to semaglutide 2.0 mg versus switching to tirzepatide.
"At EASD 2026 we are sharing the breadth and progression of our cardiometabolic portfolio and pipeline, including key insights that show how our science could make a difference in the everyday lives of people living with obesity, diabetes and related diseases,” said Martin Holst Lange, executive vice president of Research & Development and chief scientific officer at Novo. “We are presenting real-world data on Wegovy® pill, new insights into the broader benefits of semaglutide across Wegovy® and Ozempic®, and CagriSema research exploring food noise, brain responses and body composition. Together, these findings have the potential to shape the next generation of cardiometabolic care and reflect our ambition to develop treatments that can help us work towards more meaningful outcomes for patients.”
Media are invited to listen to an International Press Briefing on Wednesday, 30 September 2026, during EASD in Milan. The event will be accessible via a webcast on the Novo website, sign up via this link: Novo Nordisk: EASD International Press Briefing, 30 September 2026 (Virtual only)
Summary of presentations
Accepted data at the 62nd Annual Meeting of the EASD include the following oral presentations and short oral discussions. Accepted abstracts include preliminary data that may be subject to change in the final published manuscripts. Dates and times of the presentations can be found on the EASD website.Select Novo abstracts to be presented at EASD’s 2026 Scientific Sessions:
EASD Scientific symposium:
- REIMAGINE 1,2 and 3 Trial: Trial designs, key results and clinical perspectives: Scientific Session presentation (S21: Amylin in diabetes and obesity: What’s new?) - Wednesday 30 September; 16:30 – 17:30 CEST
Novo oral presentations and short oral discussions:
CagriSema (diabetes and obesity)
- Efficacy of CagriSema on body composition in participants with early type 2 diabetes: REIMAGINE 1. Oral presentation (LBA 11) – Tuesday 29 September; 14:45–16:15 CEST
- Effect of CagriSema on achievement of composite HbA1c and weight reduction targets in participants with type 2 diabetes: REIMAGINE 1. Oral presentation (LBA 12) – Tuesday 29 September; 14:45–16:15 CEST
- fMRI - Effects of CagriSema on appetite, eating behaviour and food cue reactivity using functional MRI in adults with overweight or obesity. Oral presentation (122) – Wednesday 30 September; 14:30–16:00 CEST
Cagrilintide
- Impact of cagrilintide 2.4 mg on physical function: post-hoc patient-reported outcomes from REDEFINE 1. Short oral discussion (593) – Tuesday 29 September; 12:00–13:00 CEST
Zenagamtide (diabetes)
- Zenagamtide (amycretin), a novel unimolecular GLP-1 and amylin receptor agonist: phase 2b results in type 2 diabetes. Oral presentation (13) – Wednesday 30 September; 9:45–11:15 CEST
Wegovy® (injection and tablets)
- OCTANE RWE US study: 3-month real-world weight outcomes among patients with overweight or obesity after switching from injectable semaglutide or tirzepatide to oral semaglutide for weight management. Short oral discussion (LBA 59) - Wednesday 30 September; 11:45–12:45 CEST
- Effect of semaglutide on liver measures and indices: pooled analysis from the STEP UP studies. Short oral discussion (529) – Thursday 1 October; 12:45–13:45 CEST
Ozempic®
- COMPETE SWITCH CV: Major adverse cardiovascular events in adults with type 2 diabetes escalating to semaglutide 2.0 mg vs switching to tirzepatide: Short oral discussion (LBA 44) – Tuesday 29 September; 12:00–13:00 CEST
- Sema 2.0-7.2 bridging: Pharmacometric modelling of escalating to subcutaneous semaglutide once-weekly 7.2 mg from 2.0 mg in a STEP UP T2D population: predicting weight reduction and gastrointestinal tolerability. Short oral discussion (824) – Tuesday 29 September; 13:15–14:15 CEST
- Post-hoc analysis from SUSTAIN FORTE: Achievement of HbA1c, body weight loss and hypoglycaemia composite endpoints with once-weekly semaglutide 2.0 mg versus 1.0 mg in T2D. Short oral discussion (828) – Tuesday 29 September; 13:15–14:15 CEST
- SUSTAIN OPTIMIZE CGM: Continuous glucose monitoring outcomes with once-weekly s.c. semaglutide 2.0 mg added to dose-reduced basal insulin vs dose-titrated basal insulin in adults with type 2 diabetes: Oral presentation (14) – Tuesday 29 September; 10:00–11:30 CEST
- FLOW mediation analysis: Evidence from mediation analysis of 72 pre-specified cardio-kidney-metabolic proteins: Oral presentation (LBA 30) – Thursday 1 October; 15:30–17:00 CEST
- FLOW trial plasma proteomics: identifies prognostic signatures and pharmacodynamic pathway modulation by semaglutide. Oral presentation (LBA 28) – Thursday 1 October; 15:30–17:00 CEST
- Semaglutide RWE in China T2D (SPOTLIGHT): Semaglutide reduces the risk of cardiovascular and renal events in Chinese type 2 diabetes patients - a real-world retrospective database study. Short oral discussion (Event A, 733) - Tuesday 29 September; 12:00-13:00
- SPOTLIGHT primary prevention: Semaglutide reduces cardiovascular event risk in the primary prevention setting among Chinese patients with type 2 diabetes: a real-world retrospective cohort study. Short oral discussion (Event A, LBA 40) - Tuesday 29 September; 12:00-13:00
- SPOTLIGHT combination therapy: Semaglutide in combination use with SGLT2i reduces cardiovascular events compared to SGLT2i alone use in Chinese patients with type 2 diabetes. Short oral discussion (Event A, LBA 42) - Tuesday 29 September; 12:00-13:00
UBT251 (diabetes and obesity):
- UBT251 (obesity), a triple hormone receptor agonist in adults with overweight or obesity: a multicenter, double-blind, placebo-controlled, randomized, phase 2 trial. Short oral discussion (Event D, 797) - Wednesday 30 September; 13:00–14:00 CEST
- UBT251 (diabetes), a triple GLP-1, GIP, and GCG receptor agonist in patients with type 2 diabetes: a multicenter, double-blind, placebo- and active-controlled, randomised, phase II trial. Oral presentation (124) - Wednesday 30 September; 14:30–16:00 CEST
Insulin Icodec
- ONWARDS 10 CGM-based metrics: Continuous glucose monitoring-based metrics in adults switching to once-weekly icodec without an initial one-time additional dose vs once-daily glargine U100. Post hoc analysis of ONWARDS 10. Short Oral discussion (Event F, 860) – Thursday 1 October; 14:00–15:00 CEST
IcoSema
- COMBINE 4 BL BMI: Efficacy and hypoglycaemia outcomes with once-weekly IcoSema vs glargine U100 in T2D by baseline BMI: COMBINE 4. Short oral discussion (854) – Thursday 1 October; 12:45–13:45 CEST
- COMBINE 4 BL HbA1c: Efficacy and hypoglycaemia outcomes with once-weekly IcoSema vs glargine U100 in T2D by baseline HbA1c: COMBINE 4. Short oral discussion (853) – Thursday 1 October; 12:45–13:45 CEST
Novo and Anthropic will collaborate to advance drug discovery with Claude
2026-09-16 14:00:00
- Collaboration aims to help Novo discover and develop new medicines faster
- Novo will use Anthropic models and Claude Science to advance scientific reasoning for Research and Development (R&D) and agentic software engineering
- This will further build on Novo’s work to become the world’s most AI-driven healthcare company
Bagsværd, Denmark, 16 September 2026 – Novo Nordisk and Anthropic today announced a collaboration that will help Novo accelerate the development of new medicines and advance AI-driven software development.
The companies will jointly address key drug discovery challenges identified by scientists and computational teams at Novo, develop targeted solutions for specific scientific challenges and workflows to support biological reasoning, and help accelerate the discovery and development of new medicines.
“This partnership is another testament to our ambition to become the world’s most AI-driven healthcare company, building on Novo’s current AI initiatives with other technology partners. Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,“ said Mike Doustdar, president and CEO of Novo. “AI can help us increase productivity in R&D and compress the path from research to marketed product. But beyond this, AI tools can also offer completely new scientific opportunities and aid reasoning and understanding of human biology and drug mechanics.”
As an initial aim, Novo will test Claude Science for specific workflows in R&D and address scientific problems where the joint capabilities of Novo and Anthropic are expected to have the greatest impact.
“AI’s increasing capability brings with it the potential to compress a century’s worth of biological and medical breakthroughs into a decade,” said Dario Amodei, co-founder and CEO of Anthropic. “By giving leading researchers access to safe, capable, and trusted frontier models, we can shorten research timelines, improve outcomes, and discover medicines and treatments that significantly improve human life. That is exactly what our collaboration with Novo is built to achieve.”
Novo will also use Anthropic’s frontier models to strengthen AI-driven software development - which is a key enabler for scaling AI across the company.
The collaboration has been designed with robust data governance and human oversight, helping ensure AI is applied responsibly and in line with Novo’s ethical and compliance standards.
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram , LinkedIn , TikTok , Facebook , X and YouTube .
1 Like
Snodig det der. De har allerede AI-avtaler med Microsoft, NVIDIA, OpenAi og nå Anthropic. De kjøper seg enten valgfrihet eller så snakker ikke den ene avdelingen med den andre. Eller så stoler de ikke på hverandre. Eller så har de ikke en sterk leder. Er de smarte eller noen rotehoder?
Må innrømme at jeg synes det vanskelig å forklare hva Novo holder på med på et rasjonelt plan.
Virker for meg som selskapet er dead set på å dekke alle mulige baser 10+ år frem i tid, samtidig som de lar relativt åpenbare hull i pipe – og med det også svekker potensialet til inntjening på 0-10 års sikt – forbli åpne.
Ganske obv. nå at GLP1/GIP-komboen vil være “backbone” i de fleste terapiene på mellomlang sikt, til noe potensielt bedre dukker opp. Har Novo en slik i pipe? Nope, de shelva sin egen i forfjor, uten å skaffe seg en erstatter. Blir som å være bilprodusent med ikke gidde å ha en vanlig stasjonsvogn i sortimentet sitt.
Ganske obv. også at ikke peptide oral small molecules vil være segmentet som utgjør “turistklasse”-varianten i fedmemarkedet. Koster niks og nada å produsere tablettene, og kan selges for $99/mnd og fortsatt tjene bøttevis med penger. I dette segmentet blir volum og lav prod. kost. nøkkelen til suksess og profitabilitet. Har Novo en eller flere slike i pipe? Nope. Oral Wegovy er fin den, men er avhengig av dagens prising vedvarer. Den er i praksis i bærbar platespiller. Jeg tror ikke den overlever walkman, når bare walkman slutter å prises som en bærbar platespiller.
En SARA? Har Novo det? Nope, de har en halvdårlig DACRA (cagrillintide), som har så som så toleranse, sammenlignet med en bra DACRA (petrelintid) og dårlig efficacy sammenlignet med en bra SARA (eloralintid).
Novo pdd er fruktboden på torget som har 3-4 kasser med fjorårets potet, men snakker om at de skal få inn litchi, kumbucha, papaya, cassava og whatnot til jul.
Nobody cares.
De må skaffe seg noen epler, årets poteter, noen appelsiner. Helst i forgårs.
3 Likes
Det vil skje igjennom oppkjøp tror jeg, angående siste der
Det er det jeg tror.
Og det er det jeg håper
Så langt synes jeg Novo har vært lite villige til å adressere dette. Og det er dessverre et sånt case hvor handling [dobbeltbetydning very much intended] sier veldig mye mer enn ord.
Skrekkscenariet for Novo er at Novo ikke klarer å innse dette, eller adressere dette på en tilfredsstillende måte.
Potensialet som turnaroundcase her er enormt, men da må det også være mulig å se for seg et Fortress Novo som både forsvarer sin andel av fedmemedikamentmarkedet fremover, og kanskje til og med kaprer segmenter av det.
Orbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion
- Agreement includes up to USD 1.4 billion with upfront and potential future milestone payments plus tiered royalties
- Novo will also make a strategic investment in Orbis Medicines
- Collaboration seeks to develop orally bioavailable macrocycle drug candidates for cardiometabolic targets
- Partnership combines Novo’s leadership in obesity and cardiometabolic disease with Orbis Medicines’ proprietary AI-enabled macrocycle discovery platform
COPENHAGEN, Denmark.
Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases. The agreement enables the acceleration of the development of a new class of orally available medicines for high-value therapeutic targets.Under the terms of the agreement, Orbis Medicines is eligible to receive up to USD 1.4 billion in upfront and potential development and commercial milestone payments, in addition to tiered royalties on future product sales. Novo will also make a strategic investment in Orbis Medicines, underscoring its confidence in the company’s nGen platform and long-term potential.
“This collaboration reinforces that the future of oral biologic drug discovery lies at the intersection of AI, proprietary experimental macrocycle datasets and world-class automated chemistry,” said Morten Graugaard, chief executive officer of Orbis Medicines. “Our nGen platform continuously learns from data generated by our high throughput chemistry and screening platform to design orally bioavailable macrocycles with the potential to replace injectable medicines. Together with Novo, we have an opportunity to unlock a new generation of oral medicines for cardiometabolic diseases and demonstrate the transformative potential of AI-enabled macrocycle drug discovery.”
The collaboration will leverage Orbis Medicines’ proprietary nGen platform, which integrates generative AI and high-throughput synthesis capabilities. The platform’s multi-parameter optimization (MPO) engine designs nCycles with good drug-like properties, continuously improved through one of the industry’s largest experimental macrocycle datasets, which Orbis is generating in real time via its lab-in-the-loop nGen platform. nGen seeks to overcome the longstanding oral bioavailability and drug-likeness limitations of macrocycles, enabling rapid discovery of differentiated oral medicines against challenging targets.
“Orbis Medicines has developed a differentiated platform for macrocycle drug discovery, combining deep expertise in macrocycle chemistry with AI-enabled molecular design,” said Brian Vandahl, senior vice president, Therapeutics Discovery, Novo. “We believe this collaboration has the potential to unlock innovative oral treatment options for patients with cardiometabolic diseases while expanding the possibilities of macrocycle therapeutics.”
Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with haemophilia A as published in the Journal of Thrombosis and Haemostasis
- FRONTIER5 data show investigational denecimig was well-tolerated with no unforeseen safety concerns after a direct switch from emicizumab, without the need for a washout period or loading dose, in people with haemophilia A aged 12 and older with or without inhibitors1
- Most patients reported the denecimig pen injector easy to use compared to their previous emicizumab vial and syringe system, as measured by a device questionnaire1
- Denecimig increased thrombin generation, a measure of blood clotting function, to levels in the normal range throughout the study period as an exploratory endpoint, without causing any excessive clotting1
Bagsværd, Denmark and Plainsboro, NJ, US, 17 September 2026 – Novo Nordisk today announced that phase 3b results from the FRONTIER5 study of investigational denecimig were published in the Journal of Thrombosis and Haemostasis. The 26-week results showed that a direct switch to the subcutaneous denecimig pen injector from the emicizumab vial and syringe injection system, without a washout period or a denecimig loading dose, was well tolerated with no unforeseen safety concerns in adolescents and adults living with haemophilia A (congenital factor VIII deficiency) with or without inhibitors. Compared to their previous emicizumab vial and syringe system, most patients preferred the denecimig pen injector and found it easier to use, as measured by the Hemophilia Device Handling and Preference Assessment (HDHPA) as a supportive secondary endpoint. Additionally, exploratory results showed thrombin peak height increased into the normal range and was sustained over 26 weeks, with no clinical evidence of excessive clotting observed after the switch from emicizumab to denecimig across all dosing frequencies.
“What stands out from the published phase 3b data is the well-tolerated switch to denecimig along with the sustained increase in thrombin generation into the normal range,” said Stephanie Seremetis, Chief Medical Officer and CVP for Rare Disease at Novo. "The positive device handling data and majority preference for our injection pen was equally encouraging, and a testament to Novo’s intentional design process with the goal of providing this patient population additional options for administration.”
In the open-label phase 3b FRONTIER5 safety study, 61 adults and adolescents aged 12 years and older with haemophilia A, with or without inhibitors, were enrolled and completed the 26-week treatment period. The primary safety endpoint of the study found that between Week 0 and Week 26 of treatment, there were 107 treatment-emergent adverse events (TEAEs) observed in 43 patients (70.5%), most of which were mild to moderate (98.1%). There were 24 TEAEs that were possibly/probably related to denecimig. Denecimig safety was found to be consistent with findings previously shared from the FRONTIER research program. No thromboembolic events, hypersensitivity reactions, or TEAEs leading to discontinuation were observed, and there was no clinical evidence of neutralizing anti-denecimig antibodies. 1
Haemophilia A is a rare, inherited bleeding disorder where a deficiency in clotting factor VIII hinders thrombin production, impairing the body’s ability to make blood clots and stop bleeding.2 A Biologics License Application (BLA) is currently under review with the US Food and Drug Administration (FDA) for denecimig as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with haemophilia A, with or without inhibitors, in once-weekly, once-every-two-weeks, or once-monthly dosing frequencies.
“Switching to a new haemophilia treatment typically requires careful spacing between treatments to avoid creating a combined, additive effect on thrombin generation," said Allison P. Wheeler, MD, University of Colorado School of Medicine, Aurora CO. "Additionally, that transition period requires close monitoring and coordination to manage gaps in protection that could increase the risk of breakthrough bleeding. Crucially, patients in the FRONTIER5 study were able to safely switch directly to denecimig without waiting until emicizumab is completely cleared from their system, and without needing an initial loading dose to jump-start their new regimen.”
A supportive secondary endpoint studied among 59 of the 61 enrolled patients showed most participants (98.3%) rated the denecimig injection pen as “easy” or “very easy” to use (Hemophilia Device Handling and Preference Assessment, HDHPA). Most patients (94.9%) reported that the denecimig injection pen was easier to use overall than their previous administration method, and most patients (96.6%) preferred the denecimig injection pen to the previous administration method. Responses were similar across each dosage frequency. See the table below for additional data.1
An additional supportive secondary endpoint studied in 55 of the 61 enrolled patients found denecimig reduced treatment burden by an average (standard deviation [SD]) of 4.7 points (9.0) at week 26, from a baseline total score of 10.5 (10.2), based on the Hemophilia Treatment Experience Measure (Hemo-TEM). See the table below for additional data.1
2 Likes